Inside MaTOS GU25: Insights from Chandler Park
The Masters in Therapeutic Oncology Summit – Genitourinary (GU) Edition (MaTOS GU25) brought together some of the brightest minds in GU oncology from March 20-23, 2025, at The Ballantyne, Charlotte.
This dynamic and highly specialized gathering fostered in-depth discussions on the latest advancements in the treatment of GU tumors. With a focus on emerging therapies, evolving treatment strategies, and complex case analyses, MaTOS-GU created a collaborative space for oncologists to exchange insights and refine approaches that will ultimately improve patient care.
At OncoDaily, we are excited to share exclusive insights from Chandler Park, Advisory Dean and Clinical Professor at University of Louisville School of Medicine, who has been closely following the event. Through his updates, we bring you key takeaways from leading oncologists as they present groundbreaking research, discuss the future of GU oncology, and share clinical expertise that is shaping the field.
- “What is the role of SBRT for patients with metastatic RCC in 2025? Dr. Chad Tang provides a data driven discussion including current prospective studies and his diagram that uses dynamic escalation/deescalation.”
2. “Dr. Hans Hammers provides guidance on when to consider IO/IO vs IO/TKI. Included in the discussion is the updated NCCN guidelines for favorable risk that includes IO/IO.”
3. “Dr. Catherine Fahey provides a great patient case (CT scan below shows great tumor shrinkage) with symptomatic disease and the potential benefit of giving a patient upfront IO/TKI for front line metastatic clear cell RCC.”
4. “Dr. Arpita Desai gives a masterful discussion of current RCC imaging guidelines, potential use of PSMA PET scan for mRCC, and future functional imaging studies.”
5. “Outstanding Keynote talk by Dr. Benjamin Maughan (GU Cancer Research Program at HuntsmanCancer) on Prostate inhibitors in earlier stages of prostate cancer. Great discussion of upcoming studies in mHSPC and localized prostate cancer with PARP inhibitors.”
6. “Dr. Karine Tawagi provides an expert discussion on Racial inequity and other social disparities in the diagnosis and management of bladder cancer.”
7. “Dr. Arpita Desai (UCSF Helen Diller Family Comprehensive Cancer Center) kicks off day 2 with a stellar discussion of molecular imaging 2025 updates in RCC.”
8. “Dr. Yousef Zakharia gives a masterful discussion of HIF2alpha inhibitors for RCC after ASCO GU25. Provides up to date information including novel HIF2alpha inhibitors.”
9. “Tour de force CAR-T cell for renal cell cancer presentation by Dr. Tanya Dorff (City of Hope). These studies are currently open for clinical trial enrollment. Preliminary studies look very promising.”
10. “Thought provoking discussion by Dr. Amanda Nizam on Prostate Cancer disparities. Great talk that demonstrate that disparities exist in the whole continuum of prostate cancer patient care.”
More posts featuring Chandler Park on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023